ALRN - American Learning Corp.

ALRN Stock Chart

ALRN Profile

Aileron Therapeutics, Inc. is a clinical-stage oncology company based in Boston, Massachusetts, specializing in the development of chemoprotection therapies. The company's primary focus is on advancing ALRN-6924, a promising candidate currently undergoing several clinical trials. These include Phase 1 trials for solid tumors and lymphoma, Phase 2a trials for peripheral T-cell lymphoma, and Phase 1 trials targeting acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS). Aileron Therapeutics is also exploring combination therapies involving ALRN-6924, such as with cytarabine (Ara-C) and palbociclib, for various oncological indications, including p53-mutated small cell lung cancer.

Founded in 2001 as Renegade Therapeutics, the company rebranded as Aileron Therapeutics, Inc. in 2007. It maintains strategic partnerships with Dana-Farber Cancer Institute and Harvard College, as well as Umicore Precious Metals Chemistry USA, LLC, to enhance its research and development capabilities in oncology treatments. Aileron Therapeutics leverages these collaborations to advance innovative therapies aimed at improving outcomes for patients with challenging cancers.

With a commitment to pioneering chemoprotection solutions, Aileron Therapeutics continues to expand its portfolio of clinical trials and research initiatives, aiming to address critical unmet medical needs in oncology. The company's dedication to advancing ALRN-6924 underscores its mission to deliver impactful therapies that offer new hope for cancer patients worldwide.

ALRN Revenue Chart

ALRN Earnings